Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558740 | 0.74 | DRD3 (0.39) | HTR2AHRH1 | |
| SCHEMBL5730541 | 0.72 | KDM1A (0.33) | HTR2A | |
| SCHEMBL17835755 | 0.69 | HTR2A (0.44) | HTR2AHRH1 | |
| SCHEMBL6630738 | 0.65 | MEN1 (0.38) | HTR2AHRH1 | |
| SCHEMBL7680505 | 0.62 | HTR2A (0.34) | HTR2AHRH1 | |
| SCHEMBL6630655 | 0.61 | EPHX2 (0.51) | — | |
| SCHEMBL29255739 | 0.61 | — | — | |
| SCHEMBL7468310 | 0.59 | ACHE (0.49) | HTR2A | |
| SCHEMBL6763552 | 0.59 | HTR2A (0.38) | HTR2AHRH1 | |
| SCHEMBL3078945 | 0.59 | HTR2A (0.38) | HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | HTR2A 3403/4885HRH1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.